157 results
8-K
EX-99.2
HRTX
Heron Therapeutics Inc
25 Mar 22
Regulation FD Disclosure
8:40am
versus Exparel ZYNRELEF will have HOPD reimbursement – 3-year pass-through ZYNRELEF offers 340B pricing Hospital Inpatient 28% (3.9M procedures) Bundled … in DRG 57% (2.2M) of inpatient procedures are done in 340B hospitals Hospital Outpatient 59% (8.3M procedures) 17% (1.4M) have Medicare reimbursement
8-K
EX-99.1
HRTX
Heron Therapeutics Inc
13 May 21
Heron Therapeutics Announces U.S. FDA Approval of ZYNRELEF™ (HTX-011) for the Management of Postoperative Pain for up to 72 Hours
8:25am
Unprecedented Value Proposition *Medicare Reimbursement only, pass-through status is for 3 years. GPO = Group Purchasing Organization. HOPD = Hospital … reimbursement with expected grant date of January 1, 2022 Like all new products, until CMS assigns a permanent code, commercial payers will require
8-K
EX-99.1
HRTX
Heron Therapeutics Inc
25 Mar 22
Regulation FD Disclosure
8:40am
Reimbursement into the Hospital Outpatient Setting of Care
- ZYNRELEF is the only local anesthetic with separate reimbursement in both the Hospital … reimbursement outside of the surgical bundle payment in the Hospital Outpatient Department (HOPD) setting of care. This CMS approval makes ZYNRELEF
CORRESP
HRTX
Heron Therapeutics Inc
10 Aug 21
Correspondence with SEC
12:00am
Services reimbursement rates for any buy-and-bill products are based on the Average Selling Price (“ASP”) of that product, including any generic products … to be reimbursed at a much higher ASP relative to the actual sale price. This period of time when generic products receive higher reimbursement rates than sale
8-K
EX-99.1
HRTX
Heron Therapeutics Inc
29 Dec 22
Other Events
9:10am
Anticipated to Provide Separate Reimbursement Outside of the Packaged Surgical Payment for ZYNRELEF
- Supplemental New Drug Application Submitted Requesting … tissue and orthopedic surgical procedures and a newly passed congressional bill that is anticipated to provide separate reimbursement outside
8-K
EX-99.2
3h2 hz1ls
2 Oct 19
Heron Announces Positive Topline Results from Phase 3b Clinical Study of HTX-011 in Total Knee Arthroplasty
7:57am
8-K
EX-99.2
wuvdngm
7 Jan 19
Heron Therapeutics Highlights Progress in Pain Management and CINV Franchises
8:36am
8-K
EX-99.1
vm8dloj5z57p
9 Aug 21
Heron Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2021 and Highlights Recent Corporate Updates
8:10am